Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kamada ( (IL:KMDA) ) has provided an update.
On May 7, 2025, Kamada Ltd. announced it will release its financial results for the first quarter of 2025 on May 14, 2025. The company will host a conference call to discuss these results, reflecting its ongoing commitment to transparency and engagement with stakeholders. This announcement underscores Kamada’s strategic focus on growth through organic commercial activities, business development, and expansion of its plasma collection operations, positioning it strongly within the biopharmaceutical industry.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies. The company focuses on treating rare and serious conditions with a portfolio that includes six FDA-approved products and other proprietary therapies. Kamada’s growth strategy involves organic growth, business development, expansion of plasma collection operations, and advancing product candidates like Inhaled AAT.
Average Trading Volume: 121,437
Current Market Cap: ILs1.4B
Learn more about KMDA stock on TipRanks’ Stock Analysis page.